ChemoCentryx, Inc.
850 Maude Avenue
Mountain View
California
94043
United States
Tel: 650-210-2900
Fax: 650-210-2910
Website: http://www.chemocentryx.com/
Email: info@chemocentryx.com
About ChemoCentryx, Inc.
"People Deserve Better Medicine and not just a longer life---a better life."
Located in the heart of the Silicon Valley, ChemoCentyx is a biotechnology company that focuses on chronic kidney diseases, immuno-oncology, and other autoimmune and inflammatory diseases.
Our vision can only be accomplished through talented people who share our culture and values.
We have created a corporate culture of scientific innovation, placing emphasis on hard work, honesty, and industry-leading technology in a fun, team-oriented atmosphere. We treat each other with respect at all times. We expect employees to add value as individuals and as team members. We work hard to nurture this environment.
As a late clinical development stage company, we are focused on a pipeline that discovers, develops and commercializes orally-administered therapeutics.
"ChemoCentryx: Great Science, Great Medicine"
179 articles with ChemoCentryx, Inc.
-
ChemoCentryx to Participate in Two Upcoming Investor Conferences
1/6/2021
ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will present at two upcoming investor conferences and participate in a panel discussion hosted by former FDA Commissioner, Scott Gottlieb, M.D.: 39th Annual J.P. Morgan Healthcare Conference Wednesday, January 13 at 11:40 a.m. Eastern Time H.C. Wainwright Virtual BioConnect Conference On-demand presentation a
-
VFMCRP and ChemoCentryx Provide Topline Results From ACCOLADE Trial of Avacopan in C3 Glomerulopathy Including Improved Estimated Glomerular Filtration Rate (eGFR)
12/21/2020
The change from baseline to week 26 in C3 glomerulopathy histologic index (C3G HI) for disease activity (primary endpoint) was not statistically different between the two treatment groups, while the C3G HI for disease chronicity
-
ChemoCentryx and VFMCRP Provide Topline Results from ACCOLADE Trial of Avacopan in C3 Glomerulopathy Including Improved Estimated Glomerular Filtration Rate (eGFR)
12/21/2020
As in ANCA vasculitis, avacopan demonstrated statistically significant improvement in renal function as measured by eGFR compared to placebo over 26 weeks of blinded treatment The change from baseline to Week 26 in C3 Glomerulopathy Histologic Index (C3G HI) for Disease Activity (primary endpoint) was not statistically different between the two treatment groups, while the C3G HI for Disease Chronicity
-
ChemoCentryx to Present at Two Upcoming Investor Conferences - Nov 19, 2020
11/19/2020
ChemoCentryx, Inc., announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will present at two upcoming investor conferences
-
Clinical Catch-Up: November 2-6
11/9/2020
It was relatively quiet in terms of COVID-19-related clinical trials, but there was still quite a bit of news for trials involving other indications. Here’s a look. -
ChemoCentryx Reports Third Quarter 2020 Financial Results and Recent Highlights
11/9/2020
-- New Drug Application (NDA ) accepted for review by U.S. Food and Drug Administration (FDA) for avacopan in ANCA -associated vasculitis with PDUFA goal date of July 7, 2021 -- -- Marketing Authorization Application (MAA) validated by the European Medicines Agency (EMA) for avacopan in ANCA-associated vasculitis -- -- T opline data from AURORA Phase II clinical trial of avacopan in Hidradenitis Suppurativa (HS) leads to Company plans
-
There was a handful of positive clinical trial news reported today. Here’s a look.
-
ChemoCentryx Announces Plenary Session at ACR Convergence 2020 to Highlight Findings of ADVOCATE Phase III Trial in ANCA-Associated Vasculitis
11/6/2020
ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that ACR Convergence 2020 -- the virtual annual meeting of the American College of Rheumatology -- will feature a plenary session presentation today on the ADVOCATE Phase III trial results of the Company’s lead drug candidate avacopan, an orally administered complement 5a receptor inhibitor,
-
VFMCRP and ChemoCentryx announce European Medicines Agency has accepted to review the Marketing Authorization Application for avacopan
11/3/2020
Vifor Fresenius Medical Care Renal Pharma Ltd. and ChemoCentryx, Inc., announced that the European Medicines Agency accepted to review the Marketing Authorization Application for avacopan for the treatment of patients with ANCA-associated vasculitis and microscopic polyangiitis ), a group of rare and severe autoimmune diseases with high need for targeted therapies.
-
ChemoCentryx to Hold Third Quarter 2020 Financial Results Conference Call on Monday, November 9, 2020
11/2/2020
ChemoCentryx, Inc., announced that the Company's third quarter 2020 financial results will be released after market close on Monday, November 9, 2020.
-
ChemoCentryx Announces Positive Topline Results of Phase II AURORA Clinical Trial of Avacopan in the Treatment of Hidradenitis Suppurativa (HS)
10/28/2020
ChemoCentryx, Inc., (Nasdaq: CCXI), today announced positive topline data from the Company’s AURORA randomized, double-blind, placebo-controlled, multi-center Phase II clinical trial of avacopan for the treatment of the chronic disabling skin disease Hidradenitis Suppurativa (HS)
-
ChemoCentryx Announces FDA Acceptance of the Avacopan New Drug Application (NDA) for the Treatment of ANCA-Associated Vasculitis
9/17/2020
ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that the U.S. Food and Drug Administration (FDA) has accepted the Company’s New Drug Application (NDA) for avacopan, an orally-administered selective complement 5a receptor inhibitor, for the treatment of ANCA-Associated Vasculitis and has set July 7, 2021 as the Prescription Drug User Fee Act (PDUFA) goal date for the avacopan NDA
-
ChemoCentryx to Present at the H.C. Wainwright 22nd Annual Global Investment Conference
9/8/2020
ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will present at the H.C. Wainwright 22nd Annual Global Investment Conference on Tuesday, September 15, 2020 at 1:30 p.m. ET. A live audio webcast of the presentation can be accessed through the Investors section of the Company's website at www.ChemoCentryx.com . A replay of the webcast will be available on the Co
-
ChemoCentryx Reports Second Quarter 2020 Financial Results and Recent Highlights
8/10/2020
ChemoCentryx, Inc. (Nasdaq: CCXI) today announced financial results for the second quarter ended June 30, 2020 and provided an overview of the Company's recent corporate highlights.
-
ChemoCentryx to Present at Two Upcoming Investor Conferences
8/4/2020
ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will present at two upcoming investor conferences in August: BTIG Virtual Biotechnology Conference 2020 Tuesday, August 11, 2020 at 11:00 a.m. Eastern Time Canaccord Genuity 40th Annual Growth Conference Wednesday, August 12, 2020 at 1:00 p.m. Eastern Time A live audio webcast of the presentations can be acces
-
ChemoCentryx to Hold Second Quarter 2020 Financial Results Conference Call on Monday, August 10, 2020
8/3/2020
ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that the Company's second quarter 2020 financial results will be released after market close on Monday, August 10, 2020. ChemoCentryx executive management will host a conference call and webcast beginning at 5:00 p.m. Eastern Time on August 10, 2020 to discuss these results and to answer questions. To participate by telephone, please dial (877) 303-8028 (Domestic) or (760) 536-5167 (I
-
ChemoCentryx Submits New Drug Application to the U.S. FDA for Avacopan in ANCA-Associated Vasculitis
7/9/2020
ChemoCentryx, Inc., (NASDAQ: CCXI) today confirmed that the Company has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for avacopan for the treatment of patients with ANCA-associated vasculitis. The Company’s NDA submission is supported by the results of its pivotal Phase III ADVOCATE trial, which demonstrated statistical superiority in sustaining remission at 52 weeks in the avacopan group compar
-
ChemoCentryx Identifies Novel Orally Administered Immune Checkpoint Inhibitor CCX559 for Next Generation Cancer Treatment
6/24/2020
Study to be presented at American Association for Cancer Research (AACR) meeting showed the Company’s orally administered small molecule checkpoint inhibitors led to marked inhibition of PD-1/PD-L1 interaction and signaling in vitro and potent anti-tumor effects in animal models
-
ChemoCentryx Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
6/15/2020
ChemoCentryx, Inc. announced the completion of its follow-on offering of 5,200,000 shares of its common stock.
-
ChemoCentryx Prices Public Offering of Common Stock
6/10/2020
ChemoCentryx, Inc. (Nasdaq:CCXI) announced today that it has priced an underwritten public offering of 5,200,000 shares of its common stock at a price to the public of $58.00 per share.